Patents by Inventor Andrew S. Felts

Andrew S. Felts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ARYLSULFONYL DERIVATIVES AND THEIR USE AS MUSCARINIC ACETYLCHOLINE RECEPTOR M5 INHIBITORS
    Publication number: 20230303552
    Abstract: Arylsulfonamides of carboxamido-piperidines, -pyrrolidines, and -azetidines, and their derivatives, are competitive and non-competitive inhibitors of the muscarinic acetylcholine receptor M5 (mAChR M5) and have utility in the treatment of psychiatric disorders such as substance-related misuse, substance- related disorder relapse, anxiety, depression, and psychosis.
    Type: Application
    Filed: June 18, 2021
    Publication date: September 28, 2023
    Inventors: Andrew S. Felts, Changho Han, Rory A. Capstick, Douglas L. Orsi, David L. Whomble, Craig W. Lindsley, P. Jeffrey Conn
  • COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5
    Publication number: 20230183237
    Abstract: Arylsulfonamides of 4-heteroaryl-piperidines, and their derivatives, are competitive and non-competitive inhibitors of the muscarinic acetylcholine receptor M5 (mAChR M5) and have utility in the treatment of psychiatric disorders such as substance-related misuse, substance-related disorder relapse, anxiety, depression, and psychosis.
    Type: Application
    Filed: May 21, 2021
    Publication date: June 15, 2023
    Inventors: Craig W. Lindsley, Carrie K. Jones, P. Jeffrey Conn, Changho Han, Andrew S. Felts, Douglas L. Orsi, Julie L. Engers, Jinming Li, Rory A. Capstick, David L. Whomble, Kayla J. Temple
  • Indazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
    Patent number: 11427573
    Abstract: Indazole compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease states associated with glutamate dysfunction.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: August 30, 2022
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Andrew S. Felts, Colleen M. Niswender, Rory A. Capstick, Paul K. Spearing, Sean R. Bollinger
  • INDAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION
    Publication number: 20220259190
    Abstract: Indazole compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease states associated with glutamate dysfunction.
    Type: Application
    Filed: April 26, 2022
    Publication date: August 18, 2022
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Andrew S. Felts, Colleen M. Niswender, Rory A. Capstick, Paul K. Spearing, Sean R. Bollinger
  • Pyridine quinoline compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
    Patent number: 11319304
    Abstract: Pyridine quinoline compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease states associated with glutamate dysfunction.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: May 3, 2022
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Andrew S. Felts, Colleen M. Niswender, Rory A. Capstick, Paul K. Spearing, Sean R. Bollinger
  • INDAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION
    Publication number: 20200291019
    Abstract: Indazole compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease states associated with glutamate dysfunction.
    Type: Application
    Filed: August 16, 2018
    Publication date: September 17, 2020
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Andrew S. Felts, Colleen M. Niswender, Rory A. Capstick, Paul K. Spearing, Sean R. Bollinger
  • PYRIDINE QUINOLINE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION
    Publication number: 20200165232
    Abstract: Pyridine quinoline compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease states associated with glutamate dysfunction.
    Type: Application
    Filed: June 28, 2018
    Publication date: May 28, 2020
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Andrew S. Felts, Colleen M. Niswender, Rory A. Capstick, Paul K. Spearing, Sean R. Bollinger
  • 4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators
    Patent number: 10538491
    Abstract: 4,5-Substituted Picolinamide and picolinonitrile compounds of formula (I), where R4 is CONH2 or CN and R1 is an optionally substituted aryl or heteroaryl, are negative allosteric modulators of the metabotropic glutamate receptor 2 (mGlu2). The compounds and pharmaceutical compositions including the compounds may be useful for treating depression, anxiety, obsessive-compulsive disorder, cognitive disorders, Alzheimer's disease, or autism spectrum disorders in a subject.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: January 21, 2020
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Kyle A. Emmitte, Andrew S. Felts, Katrina A. Bollinger
  • Indazole compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
    Patent number: 10508105
    Abstract: Indazole compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease states associated with glutamate dysfunction.
    Type: Grant
    Filed: August 16, 2018
    Date of Patent: December 17, 2019
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Andrew S. Felts, Colleen M. Niswender, Rory A. Capstick, Paul K. Spearing, Sean R. Bollinger
  • Positive allosteric modulators of the muscarinic acetylcholine receptor M4
    Patent number: 10342782
    Abstract: Disclosed herein are thieno[3,2-e][1,2,4]triazolo[1,5-a]pyridin-6-amine, thieno[3,2-e][1,2,4]triazolo[4,3-a]pyridin-3-amine, and imidazo[1,2-a]thieno[3,2-e]pyridin-3-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: July 9, 2019
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Darren W. Engers, Carrie K. Jones, Thomas M. Bridges, Changho Han, Andrew S. Felts
  • INDAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION
    Publication number: 20190055225
    Abstract: Indazole compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease states associated with glutamate dysfunction.
    Type: Application
    Filed: August 16, 2018
    Publication date: February 21, 2019
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Andrew S. Felts, Colleen M. Niswender, Rory A. Capstick, Paul K. Spearing, Sean R. Bollinger
  • NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2
    Publication number: 20180072674
    Abstract: Described are negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating depression, anxiety, obsessive-compulsive disorder, cognitive disorders, Alzheimer's disease, or autism spectrum disorders in a subject.
    Type: Application
    Filed: March 16, 2016
    Publication date: March 15, 2018
    Applicant: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Kyle A. Emmitte, Andrew S. Felts, Katrina A. Bollinger
  • POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4
    Publication number: 20180028501
    Abstract: Disclosed herein are thieno[3,2-e][1,2,4]triazolo[1,5-a]pyridin-6-amine, thieno[3,2-e][1,2,4]triazolo[4,3-a]pyridin-3-amine, and imidazo[1,2-a]thieno[3,2-e]pyridin-3-amine compounds, which may be useful as positive allosteric modulators of the muscarinic acetylcholine receptor M4 (mAChR M4). Also disclosed herein are methods of making the compounds, pharmaceutical compositions comprising the compounds, and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.
    Type: Application
    Filed: July 27, 2017
    Publication date: February 1, 2018
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Darren W. Engers, Carrie K. Jones, Thomas M. Bridges, Changho Han, Andrew S. Felts
  • Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mGluR5
    Patent number: 9844542
    Abstract: Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: December 19, 2017
    Assignee: Vanderbilt University
    Inventors: Kyle A. Emmitte, Craig W. Lindsley, P. Jeffrey Conn, Andrew S. Felts, Alice L. Rodriguez, Katrina A. Smith, Carrie K. Jones
  • SUBSTITUTED 4-ALKOXYPICOLINAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20170247366
    Abstract: Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: June 25, 2015
    Publication date: August 31, 2017
    Inventors: Kyle A. EMMITTE, Craig W. LINDSLEY, P. Jeffrey CONN, Andrew S. FELTS, Katrina A. Bollinger
  • Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
    Patent number: 9550778
    Abstract: Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: January 24, 2017
    Assignee: Vanderbilt University
    Inventors: Kyle A. Emmitte, Craig W. Lindsley, P. Jeffrey Conn, Andrew S. Felts, Katrina A. Smith
  • Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators
    Patent number: 9533982
    Abstract: Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: January 3, 2017
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Kyle A. Emmitte, Andrew S. Felts
  • SUBSTITUTED IMIDAZOPYRIDINE AND TRIAZOLOPYRIDINE COMPOUNDS AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR5
    Publication number: 20160289227
    Abstract: Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: November 18, 2014
    Publication date: October 6, 2016
    Inventors: Kyle A. Emmitte, Craig W. Lindsley, P. Jeffrey Conn, Andrew S. Felts, Alice L. Rodriguez, Katrina A. Smith, Carrie K. Jones
  • NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2
    Publication number: 20160214940
    Abstract: Described are negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating depression, anxiety, obsessive-compulsive disorder, cognitive disorders, Alzheimer's disease, or autism spectrum disorders in a subject.
    Type: Application
    Filed: January 26, 2016
    Publication date: July 28, 2016
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Kyle A. Emmitte, Andrew S. Felts, Katrina A. Bollinger
  • Negative allosteric modulators of metabotropic glutamate receptor 2
    Patent number: 9382208
    Abstract: Described are negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu2), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating depression, anxiety, obsessive-compulsive disorder, cognitive disorders, Alzheimer's disease, or autism spectrum disorders in a subject.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: July 5, 2016
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Kyle A. Emmitte, Andrew S. Felts, Katrina A. Bollinger